IDIOPATHIC PULMONARY FIBROSIS (IPF)

This study is testing whether a new oral medication called buloxibutid can help slow the decline of lung function in people with idiopathic pulmonary fibrosis (IPF). Over 52 weeks, 360 participants will take either one of two doses of the drug or a placebo pill, while researchers…

This early-stage study is testing the safety and how the body processes a new inhaled powder version of a drug called nintedanib in people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. The trial will enroll about 24 patients to see if inhaling the dru…

This study aims to check the long-term safety and side effects of an inhaled medication for people with progressive lung scarring (pulmonary fibrosis). It is open to people who have already completed a previous study with this type of inhaled drug. Participants will use the medic…

This study is testing a new oral drug called INS018_055 in 40 adults with Idiopathic Pulmonary Fibrosis (IPF), a serious lung-scarring disease. The main goal is to check the drug's safety and how the body processes it over 12 weeks. Researchers will also look for early signs that…

This study is testing a new oral drug called SB17170 for people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. About 30 patients will take either the drug or a placebo pill daily for 12 weeks to see if it helps slow the decline in lung function and imp…

This study is testing an experimental inhaled medicine called LTI-03 for people with Idiopathic Pulmonary Fibrosis (IPF), a serious disease that causes progressive lung scarring. About 120 participants will use an inhaler with either LTI-03 or a placebo for 24 weeks to see if the…

This study is testing an experimental drug called SV001 in people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. The main goal is to check if the drug is safe and how the body processes it. Researchers will give the drug to 48 patients and compare them…

This study is testing whether a natural supplement called quercetin can help control progressive lung scarring (fibrosis) in people with certain lung diseases. One hundred patients will be randomly assigned to take either quercetin plus their standard care or just standard care a…

This study is testing a new, more efficient way for patients with chronic lung scarring diseases (like pulmonary fibrosis) to attend their regular hospital check-ups. Currently, these visits can be spread over multiple days, requiring separate trips for tests and doctor appointme…

This study is testing whether a more organized and faster diagnostic process can reduce the time it takes for patients to get a clear diagnosis for suspected interstitial lung disease (ILD). It will compare the current standard, often fragmented process to a new, coordinated appr…

This study aims to collect blood, urine, and airway samples from both healthy people and people with lung diseases like COPD and pulmonary fibrosis. Researchers will compare the samples to understand what causes these diseases and how they develop. The goal is to gather basic inf…

This study aims to better understand how rheumatoid arthritis affects the lungs by carefully analyzing detailed chest scans. Researchers will compare scan patterns from 500 adults with rheumatoid arthritis to those from people with other lung diseases. The goal is to identify spe…

This study aims to understand how anti-fibrotic medications for lung fibrosis affect patients' body composition—specifically fat and muscle—which regular weight checks might miss. Researchers will use quick, non-invasive scans (bioimpedance analysis and muscle ultrasound) on 30 p…